Emerging Drugs and Targets for Alzheimer's Disease: Two volume set

Overview

Alzheimer's disease is the most prevalent type of neurodegenerative disorder in the elderly. A recent study from Bloomberg School of Public Health estimated that more than 26 million people worldwide were living with the disease in 2006 and that the global prevalence of the disease will grow to more than 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the ...

See more details below
Available through our Marketplace sellers.
Other sellers (Hardcover)
  • All (1) from $207.86   
  • New (1) from $207.86   
Close
Sort by
Page 1 of 1
Showing All
Note: Marketplace items are not eligible for any BN.com coupons and promotions
$207.86
Seller since 2010

Feedback rating:

(55)

Condition:

New — never opened or used in original packaging.

Like New — packaging may have been opened. A "Like New" item is suitable to give as a gift.

Very Good — may have minor signs of wear on packaging but item works perfectly and has no damage.

Good — item is in good condition but packaging may have signs of shelf wear/aging or torn packaging. All specific defects should be noted in the Comments section associated with each item.

Acceptable — item is in working order but may show signs of wear such as scratches or torn packaging. All specific defects should be noted in the Comments section associated with each item.

Used — An item that has been opened and may show signs of wear. All specific defects should be noted in the Comments section associated with each item.

Refurbished — A used item that has been renewed or updated and verified to be in proper working condition. Not necessarily completed by the original manufacturer.

New
"New, ships through UPS and DHL. Excellent customer service. Satisfaction guaranteed!! "

Ships from: STERLING HEIGHTS, MI

Usually ships in 1-2 business days

  • Canadian
  • International
  • Standard, 48 States
  • Standard (AK, HI)
Page 1 of 1
Showing All
Close
Sort by
Sending request ...

Overview

Alzheimer's disease is the most prevalent type of neurodegenerative disorder in the elderly. A recent study from Bloomberg School of Public Health estimated that more than 26 million people worldwide were living with the disease in 2006 and that the global prevalence of the disease will grow to more than 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease's progression were made, it could have a huge impact on global public health. According to this study, interventions that could delay the onset of the disease by as little as one year would reduce the prevalence of the disease by 12 million fewer cases in 2050. These figures reinforce how important it is to find an effective therapeutic intervention for Alzheimer's disease. Emerging Drugs and Targets for Alzheimer's Disease collects some of the most outstanding examples of new drugs currently in pharmaceutical development or new targets under the validation process that will reach the Alzheimer's drug market over the next few years as disease modifying drugs. Written by a team of distinguished experts these books will be an essential resource for scientists in the pharmaceutical and biotechnology industries and academics working in the drugs for neurodegeneration field.

Read More Show Less

Product Details

  • ISBN-13: 9781849730457
  • Publisher: Royal Society of Chemistry, The
  • Publication date: 6/25/2010
  • Series: RSC Drug Discovery Series
  • Edition number: 1
  • Pages: 668
  • Product dimensions: 7.38 (w) x 11.76 (h) x 1.99 (d)

Meet the Author

Ana Martinez obtained her PhD in Organic Chemistry from the Complutense University of Madrid before becoming a researcher at the Medicinal Chemistry Institute of the Spanish National Council for Research (CSIC). Since 1995, her interests have focused on neurodegenerative disorders and she has led numerous research projects on the medicinal chemistry and rational drug design with the aim of finding new treatments for Alzheimer's disease. In February 2002, she joined NeuroPharma (now NOSCIRA) as R&D Director where she led projects from the discovery of potential new therapies to the final proof of concept in animal models. In February 2008, she returned to her academic position at the Medicinal Chemistry Institute (CSIC) leading several projects on neurodegenerative disease therapies and acting as an external scientific advisor to a number of pharmaceutical companies. Her main areas of research currently involve GSK-3 inhibitors and dual binding site acetylcholinesterase inhibitors. She has authored over a hundred and fifty scientific publications and has more than twenty active patents in the field.

Read More Show Less

Table of Contents

VOLUME 1; Beta-Amyloid as target; Chapter 1: The amyloid hypothesis of AD and prospects for therapeutics; Chapter 2: Targeting Alzheimer's δ-Secretase: Genetic and Chemical Modulation; Chapter 3: Cholesterol and AD: the molecules, the targets; Chapter 4: The Bimodal Features of Butyrylcholinesterase in Cholinergic Neurotransmission and Amyloid Suppression; Chapter 5: Scyllo-inositol, a potential therapy for Alzheimer's disease; Chapter 6: Immunotherapeutic strategies toward treatment of AD; Tau protein as target; Chapter 7: Alzheimer Neurofibrillary Degeneration: Pivotal Role and Therapeutic Targets; Chapter 8: Multiple roles of glycogen synthase kinase-3 in AD; Chapter 9: Tau protein kinases inhibitors: from the bench to the clinical trials; Chapter 10: Activating PP2A as a therapeutic intervention strategy in AD; Chapter 11: Rationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies; Glucose Metabolism as target; Chapter 12: Insulin Insulin Resistance and neurodegeneration: Type 2 versus type 3 diabetes mellitus; Chapter 13: Insulin-like Growth Factor I as a disease-modifying therapy in Alzheimer's disease; Chapter 14: Ketone bodies as a therapeutic for Alzheimer's disease; VOLUME 2 Neuronal Plasticity as target; Chapter 15: Regeneration of Degenerated Brain: A Promising Therapeutic Target; Chapter 16: Promoting synaptic resilience in AD patients through PDE inhibition; Chapter 17: A new generation of non invasive NGF-based therapies for Alzheimer's disease; Chapter 18: Possible clinical applications of stem cell strategies in AD therapies; Neuronal protection as target; Chapter 19: Targeting Oxidative Mechanisms in Alzheimer Disease; Chapter 20: Davunetide (NAP) Pharmacology: Neuroprotection and tau; Chapter 21: Targeting NF- B inflammatory and pro-survival signaling in AD; Chapter 22: PPAR in Alzheimer's disease; Miscellaneous targets and strategies; Chapter 23: Serotonin 5-HT4 receptors as pharmacological targets for the treatment of Alzheimer's disease; Chapter 24: Liver X Receptors as potential therapeutic target for AD; Chapter 25: Discovery of memoquin, a multi-target-directed ligand for the treatment of Alzheimer's disease Chapter 26. RNA interference of genes related to AD B. Nawrot Chapter 27. Medicinal plants, phytochemicals and Alzheimer's Disease D. Kennedy

Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)